Skip to main content

Advertisement

SpringerLink
Log in

Vitamins, metabolomics, and prostate cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

How micronutrients might influence risk of developing adenocarcinoma of the prostate has been the focus of a large body of research (especially regarding vitamins E, A, and D). Metabolomic profiling has the potential to discover molecular species relevant to prostate cancer etiology, early detection, and prevention, and may help elucidate the biologic mechanisms through which vitamins influence prostate cancer risk.

Methods

Prostate cancer risk data related to vitamins E, A, and D and metabolomic profiling from clinical, cohort, and nested case–control studies, along with randomized controlled trials, are examined and summarized, along with recent metabolomic data of the vitamin phenotypes.

Results

Higher vitamin E serologic status is associated with lower prostate cancer risk, and vitamin E genetic variant data support this. By contrast, controlled vitamin E supplementation trials have had mixed results based on differing designs and dosages. Beta-carotene supplementation (in smokers) and higher circulating retinol and 25-hydroxy-vitamin D concentrations appear related to elevated prostate cancer risk. Our prospective metabolomic profiling of fasting serum collected 1–20 years prior to clinical diagnoses found reduced lipid and energy/TCA cycle metabolites, including inositol-1-phosphate, lysolipids, alpha-ketoglutarate, and citrate, significantly associated with lower risk of aggressive disease.

Conclusions

Several active leads exist regarding the role of micronutrients and metabolites in prostate cancer carcinogenesis and risk. How vitamins D and A may adversely impact risk, and whether low-dose vitamin E supplementation remains a viable preventive approach, require further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Nicholson JK, Lindon JC (2008) Systems biology: metabolomics. Nature 455(7216):1054–1056

    Article  CAS  PubMed  Google Scholar 

  2. O’Connell TM (2012) Recent advances in metabolomics in oncology. Bioanalysis 4(4):431–451

    Article  PubMed  Google Scholar 

  3. Office of Dietary Supplements N (2015) Vitamin E fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminEHealthProfessional/. Accessed 22 June 2016

  4. Wagner KH, Kamal-Eldin A, Elmadfa I (2004) Gamma-tocopherol—an underestimated vitamin? Ann Nutr Metab 48(3):169–188

    Article  CAS  PubMed  Google Scholar 

  5. Brigelius-Flohe R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM, Azzi A (2002) The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr 76(4):703–716

    CAS  PubMed  Google Scholar 

  6. Ricciarelli R, Zingg JM, Azzi A (2001) Vitamin E: protective role of a Janus molecule. FASEB J 15(13):2314–2325

    Article  CAS  PubMed  Google Scholar 

  7. The ATBC Cancer Prevention Study Group (1994) The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 4(1):1–10

    Google Scholar 

  8. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90(6):440–446

    Article  CAS  PubMed  Google Scholar 

  9. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330(15):1029–1035

    Article  Google Scholar 

  10. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR (2005) Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293(11):1338–1347

    Article  PubMed  Google Scholar 

  11. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Sesso HD, Buring JE (2009) Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA 301(1):52–62

    Article  CAS  PubMed  Google Scholar 

  12. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD III, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin e cancer prevention trial (SELECT). JAMA 301(1):39–51

    Article  CAS  PubMed  Google Scholar 

  13. Klein E, Thompson I, Tangen C, Crowley J, Lucia M, Goodman P, Minasian L, Ford L, Parnes H, Gaziano J, Karp D, Lieber M, Walther P, Klotz L, Parsons J, Chin J, Darke A, Lippman S, Goodman G, Meyskens F, Baker L (2011) Vitamin E and the risk of prostate cancer. The selenium and vitamin e cancer prevention trial (SELECT). JAMA 306(14):1549–1556

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, Estaquio C, Hercberg S (2005) Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 116(2):182–186

    Article  CAS  PubMed  Google Scholar 

  15. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):23–33

    Article  Google Scholar 

  16. Gann PH (2009) Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance—next, cause. JAMA 301(1):102–103. doi:10.1001/jama.2008.863

    Article  CAS  PubMed  Google Scholar 

  17. Cheng T, Barnett M, Kristal A, Ambrosone C, King I, Thornquist M, Goodman G, Neuhouser M (2011) Genetic variation in myeloperoxidase modifies the association of serum alpha-tocopherol with aggressive prostate cancer among current smokers. J Nutr 141(9):1731–1737

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Goodman GE, Schaffer S, Omenn GS, Chen C, King I (2003) The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomark Prev 12(6):518–526

    CAS  Google Scholar 

  19. Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bernasconi F (1996) Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 66(2):145–150

    Article  CAS  PubMed  Google Scholar 

  20. Rodriguez C, Jacobs EJ, Mondul AM, Calle EE, McCullough ML, Thun MJ (2004) Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomark Prev 13(3):378–382

    CAS  Google Scholar 

  21. Weinstein SJ, Wright ME, Pietinen P, King I, Tan C, Taylor PR, Virtamo J, Albanes D (2005) Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 97(5):396–399

    Article  CAS  PubMed  Google Scholar 

  22. Watters JL, Gail MH, Weinstein SJ, Virtamo J, Albanes D (2009) Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival. Cancer Res 69(9):3833–3841. doi:10.1158/0008-5472.CAN-08-4640

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Weinstein SJ, Wright ME, Lawson KA, Snyder K, Mannisto S, Taylor PR, Virtamo J, Albanes D (2007) Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol Biomark Prev 16(6):1253–1259

    Article  CAS  Google Scholar 

  24. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL (1999) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomark Prev 8(10):893–899

    CAS  Google Scholar 

  25. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 59(6):1225–1230

    CAS  PubMed  Google Scholar 

  26. Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, Albanes D, Andriole GL, Urban DA, Peters U (2006) Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 98(4):245–254

    Article  CAS  PubMed  Google Scholar 

  27. Peters U, Littman AJ, Kristal AR, Patterson RE, Potter JD, White E (2008) Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control 19(1):75–87

    Article  PubMed  Google Scholar 

  28. Wright ME, Weinstein SJ, Lawson KA, Albanes D, Subar AF, Dixon LB, Mouw T, Schatzkin A, Leitzmann MF (2007) Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol Biomark Prev 16(6):1128–1135

    Article  CAS  Google Scholar 

  29. Gill JK, Franke AA, Steven MJ, Cooney RV, Wilkens LR, Le ML, Goodman MT, Henderson BE, Kolonel LN (2009) Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control 20(7):1161–1171. doi:10.1007/s10552-009-9304-4

    Article  PubMed  PubMed Central  Google Scholar 

  30. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E (2007) Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European prospective investigation into cancer and nutrition study. Am J Clin Nutr 86(3):672–681

    CAS  PubMed  Google Scholar 

  31. Key TJ, Appleby PN, Travis RC, Albanes D, Alberg AJ, Barricarte A, Black A, Boeing H, Bueno-de-Mesquita HB, Chan JM, Chen C, Cook MB, Donovan JL, Galan P, Gilbert R, Giles GG, Giovannucci E, Goodman GE, Goodman PJ, Gunter MJ, Hamdy FC, Heliovaara M, Helzlsouer KJ, Henderson BE, Hercberg S, Hoffman-Bolton J, Hoover RN, Johansson M, Khaw KT, King IB, Knekt P, Kolonel LN, Le ML, Mannisto S, Martin RM, Meyer HE, Mondul AM, Moy KA, Neal DE, Neuhouser ML, Palli D, Platz EA, Pouchieu C, Rissanen H, Schenk JM, Severi G, Stampfer MJ, Tjonneland A, Touvier M, Trichopoulou A, Weinstein SJ, Ziegler RG, Zhou CK, Allen NE (2015) Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. Am J Clin Nutr 102(5):1142–1157. doi:10.3945/ajcn.115.114306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Major JM, Yu K, Wheeler W, Zhang H, Cornelis MC, Wright ME, Yeager M, Snyder K, Weinstein SJ, Mondul A, Eliassen H, Purdue M, Hazra A, McCarty CA, Hendrickson S, Virtamo J, Hunter D, Chanock S, Kraft P, Albanes D (2011) Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum Mol Genet. doi:10.1093/hmg/ddr296

    Google Scholar 

  33. Major JM, Yu K, Weinstein SJ, Berndt SI, Hyland PL, Yeager M, Chanock S, Albanes D (2014) Genetic variants reflecting higher vitamin E status in men are associated with reduced risk of prostate cancer. J Nutr 144(5):729–733. doi:10.3945/jn.113.189928

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll PR, Chan JM (2013) Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence. Prostate 73(16):1786–1795. doi:10.1002/pros.22717

    Article  CAS  PubMed  Google Scholar 

  35. Wright ME, Peters U, Gunter MJ, Moore SC, Lawson KA, Yeager M, Weinstein SJ, Snyder K, Virtamo J, Albanes D (2009) Association of variants in two vitamin E transport genes with circulating vitamin e concentrations and prostate cancer risk. Cancer Res 69(4):1429–1438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Ross AC (1999) Vitamin A and retinoids. In: Shils ME, Olson JA, Shike M, Ross AC (eds) Modern nutrition in health and disease, 9th edn. Lippincott Williams & Wilkins, Baltimore, pp 305–327

    Google Scholar 

  37. Peehl DM, Feldman D (2003) The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer 10(2):131–140

    Article  CAS  PubMed  Google Scholar 

  38. Mondul AM, Watters JL, Mannisto S, Weinstein SJ, Snyder K, Virtamo J, Albanes D (2011) Serum retinol and risk of prostate cancer. Am J Epidemiol 173(7):813–821. doi:10.1093/aje/kwq429

    Article  PubMed  PubMed Central  Google Scholar 

  39. Office of Dietary Supplements N (2015) Vitamin A fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminAHealthProfessional/. Accessed 22 June 2016

  40. Krinsky NI, Johnson EJ (2005) Carotenoid actions and their relation to health and disease. Mol Asp Med 26(6):459–516. doi:10.1016/j.mam.2005.10.001

    Article  CAS  Google Scholar 

  41. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA, Hammar S (1996) Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J Natl Cancer Inst 88(21):1550–1559

    Article  CAS  PubMed  Google Scholar 

  42. Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH (2000) Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians’ Health Study (United States). Cancer Causes Control 11(7):617–626

    Article  CAS  PubMed  Google Scholar 

  43. Wright ME, Groshong SD, Husgafvel-Pursiainen K, Genova E, Lucia MS, Wolff H, Virtamo J, Albanes D (2010) Effects of beta-carotene supplementation on molecular markers of lung carcinogenesis in male smokers. Cancer Prev Res 3(6):745–752. doi:10.1158/1940-6207.CAPR-09-0107

    Article  CAS  Google Scholar 

  44. Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF (1988) Serum levels of selenium and retinol and the subsequent risk of cancer. Am J Epidemiol 128(3):515–523

    Article  CAS  PubMed  Google Scholar 

  45. Cook NR, Stampfer MJ, Ma J, Manson JE, Sacks FM, Buring JE, Hennekens CH (1999) Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer 86(9):1783–1792. doi:10.1002/(SICI)1097-0142(19991101)86:9<1783:AID-CNCR21>3.0.CO;2-N

    Article  CAS  PubMed  Google Scholar 

  46. Nash SH, Till C, Song X, Lucia MS, Parnes HL, Thompson IM Jr, Lippman SM, Platz EA, Schenk J (2015) Serum retinol and carotenoid concentrations and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 24(10):1507–1515. doi:10.1158/1055-9965.EPI-15-0394

    Article  Google Scholar 

  47. Wang Y, Cui R, Xiao Y, Fang J, Xu Q (2015) Effect of carotene and lycopene on the risk of prostate cancer: a systematic review and dose-response meta-analysis of observational studies. PLoS ONE 10(9):e0137427. doi:10.1371/journal.pone.0137427

    Article  PubMed  PubMed Central  Google Scholar 

  48. Ferrucci L, Perry JR, Matteini A, Perola M, Tanaka T, Silander K, Rice N, Melzer D, Murray A, Cluett C, Fried LP, Albanes D, Corsi AM, Cherubini A, Guralnik J, Bandinelli S, Singleton A, Virtamo J, Walston J, Semba RD, Frayling TM (2009) Common variation in the beta-carotene 15,15′-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet 84(2):123–133. doi:10.1016/j.ajhg.2008.12.019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Mondul AM, Yu K, Wheeler W, Zhang H, Weinstein SJ, Major JM, Cornelis MC, Mannisto S, Hazra A, Hsing AW, Jacobs KB, Eliassen H, Tanaka T, Reding DJ, Hendrickson S, Ferrucci L, Virtamo J, Hunter DJ, Chanock SJ, Kraft P, Albanes D (2011) Genome-wide association study of circulating retinol levels. Hum Mol Genet 20(23):4724–4731. doi:10.1093/hmg/ddr387

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. IARC (2009) Vitamin D and cancer. Lyon, France

    Google Scholar 

  51. Yin L, Raum E, Haug U, Arndt V, Brenner H (2009) Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 33(6):435–445

    Article  CAS  PubMed  Google Scholar 

  52. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P (2011) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128(6):1414–1424. doi:10.1002/ijc.25439

    Article  CAS  PubMed  Google Scholar 

  53. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, Bekkering GE, Fraser WD, Sterne JA, Metcalfe C (2011) Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22(3):319–340. doi:10.1007/s10552-010-9706-3

    Article  PubMed  Google Scholar 

  54. Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN (2010) Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer 46(5):932–936

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjonneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kroger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larranaga N, Gonzalez CA, Arguelles MV, Sanchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ (2009) Serum vitamin D and risk of prostate cancer in a case–control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 169(10):1223–1232

    Article  PubMed  PubMed Central  Google Scholar 

  56. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB (2008) Serum vitamin D concentration and prostate cancer risk: a nested case–control study. J Natl Cancer Inst 100(11):796–804

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J, Hakama M (2007) Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomark Prev 16(2):302–307

    Article  CAS  Google Scholar 

  58. Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS, Heber D, Greenberg ER (2005) Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomark Prev 14(3):586–589. doi:10.1158/1055-9965.EPI-04-0319

    Article  CAS  Google Scholar 

  59. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15(3):255–265

    Article  PubMed  Google Scholar 

  60. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case–control study in the Nordic countries. Int J Cancer 108(1):104–108

    Article  CAS  PubMed  Google Scholar 

  61. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW (1995) Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6(3):235–239

    Article  CAS  PubMed  Google Scholar 

  62. Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J, Weinstein SJ (2011) Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case–control study. Cancer Epidemiol Biomark Prev 20(9):1850–1860. doi:10.1158/1055-9965.EPI-11-0403

    Article  CAS  Google Scholar 

  63. Weinstein SJ, Mondul AM, Kopp W, Rager H, Virtamo J, Albanes D (2013) Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer 132(12):2940–2947. doi:10.1002/ijc.27969

    Article  CAS  PubMed  Google Scholar 

  64. Xu Y, Shao X, Yao Y, Xu L, Chang L, Jiang Z, Lin Z (2014) Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol 140(9):1465–1477. doi:10.1007/s00432-014-1706-3

    Article  CAS  PubMed  Google Scholar 

  65. Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, Kristal AR, Peters U, Neuhouser ML (2014) Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 23(8):1484–1493. doi:10.1158/1055-9965.EPI-13-1340

    Article  CAS  Google Scholar 

  66. Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA (2014) Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E cancer prevention trial. Cancer Epidemiol Biomark Prev 23(8):1494–1504. doi:10.1158/1055-9965.EPI-14-0115

    Article  CAS  Google Scholar 

  67. McCullough ML, Bostick RM, Mayo TL (2009) Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 29:111–132

    Article  CAS  PubMed  Google Scholar 

  68. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, Jacobs EJ, Ascherio A, Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, Virtamo J, Horst R, Wheeler W, Chanock S, Hunter DJ, Hayes RB, Kraft P, Albanes D (2010) Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 19(13):2739–2745. doi:10.1093/hmg/ddq155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O’Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, Jarvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hypponen E, Spector TD (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376(9736):180–188. doi:10.1016/S0140-6736(10)60588-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Mondul AM, Shui IM, Yu K, Travis RC, Stevens VL, Campa D, Schumacher F, Ziegler RG, Bueno-de-Mesquita HB, Berndt SI, Crawford ED, Gapstur SM, Gaziano JM, Giovannucci E, Haiman C, Henderson BE, Hunter DJ, Johansson M, Key TJ, Le ML, Lindstrom S, McCullough M, Navarro C, Overvad K, Palli D, Purdue MP, Stampfer MJ, Weinstein SJ, Willett W, Yeager M, Chanock SJ, Trichopoulos D, Kolonel LN, Kraft P, Albanes D (2013) Genetic variation in the vitamin D pathway in relation to risk of prostate cancer—results from breast and prostate cancer cohort consortium (BPC3). Cancer Epidemiol Biomark Prev. doi:10.1158/1055-9965.EPI-13-0007-T

    Google Scholar 

  71. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85(6):1586–1591

    CAS  PubMed  Google Scholar 

  72. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O’Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, Prentice RL, Robbins J, Rohan TE, Sarto GE, Sharma S, Stefanick ML, Van HL, Wallace RB, Whitlock E, Bassford T, Beresford SA, Black HR, Bonds DE, Brzyski RG, Caan B, Chlebowski RT, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Judd H, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, Manson JE (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354(7):684–696

    Article  CAS  PubMed  Google Scholar 

  73. Trivedi D, Doll R, Khaw K (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326(7387):469

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, Grant AM, Campbell MK, Anderson FH, Cooper C, Francis RM, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA (2012) Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab 97(2):614–622. doi:10.1210/jc.2011-1309

    Article  CAS  PubMed  Google Scholar 

  75. Fortmann SP, Burda BU, Senger CA, Lin J, Beil T, O’Connor E, Whitlock EP (2013) Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: a systematic evidence review for the U.S. preventive services task force. Evidence Report No. 108, AHRQ Publication No. 14-05199-EF-1. Agency for Healthcare Research and Quality, Rockville, MD

  76. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM, Buring JE (2012) The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 33(1):159–171. doi:10.1016/j.cct.2011.09.009

    Article  CAS  PubMed  Google Scholar 

  77. Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K, Virtamo J (2009) Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 101(18):1272–1279. doi:10.1093/jnci/djp260

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Wehr E, Pilz S, Boehm BO, Marz W, Obermayer-Pietsch B (2010) Association of vitamin D status with serum androgen levels in men. Clin Endocrinol 73(2):243–248. doi:10.1111/j.1365-2265.2009.03777.x

    CAS  Google Scholar 

  79. Mondul AM, Sampson JN, Moore SC, Weinstein SJ, Evans AM, Karoly ED, Virtamo J, Albanes D (2013) Metabolomic profile of response to supplementation with beta-carotene in the alpha-tocopherol, beta-carotene cancer prevention study. Am J Clin Nutr 98(2):488–493. doi:10.3945/ajcn.113.062778

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Liu C, Russell RM, Wang XD (2003) Exposing ferrets to cigarette smoke and a pharmacological dose of beta-carotene supplementation enhance in vitro retinoic acid catabolism in lungs via induction of cytochrome P450 enzymes. J Nutr 133(1):173–179

    CAS  PubMed  Google Scholar 

  81. Paolini M, Antelli A, Pozzetti L, Spetlova D, Perocco P, Valgimigli L, Pedulli GF, Cantelli-Forti G (2001) Induction of cytochrome P450 enzymes and over-generation of oxygen radicals in beta-carotene supplemented rats. Carcinogenesis 22(9):1483–1495

    Article  CAS  PubMed  Google Scholar 

  82. Johnson CH, Slanar O, Krausz KW, Kang DW, Patterson AD, Kim JH, Luecke H, Gonzalez FJ, Idle JR (2012) Novel metabolites and roles for alpha-tocopherol in humans and mice discovered by mass spectrometry-based metabolomics. Am J Clin Nutr 96(4):818–830. doi:10.3945/ajcn.112.042929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Wong M, Lodge JK (2012) A metabolomic investigation of the effects of vitamin E supplementation in humans. Nutr Metab 9(1):1–9. doi:10.1186/1743-7075-9-110

    Article  Google Scholar 

  84. Nelson SM, Panagiotou OA, Anic GM, Mondul AM, Männistö S, Weinstein SJ, Albanes D (2016) A metabolomics analysis of serum 25-hydroxy-vitamin D in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Epidemiol (in press)

  85. Lloyd SM, Arnold J, Sreekumar A (2015) Metabolomic profiling of hormone-dependent cancers: a bird’s eye view. Trends Endocrinol Metab 26(9):477–485. doi:10.1016/j.tem.2015.07.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Trock BJ (2011) Application of metabolomics to prostate cancer. Urol Oncol 29(5):572–581. doi:10.1016/j.urolonc.2011.08.002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Mondul AM, Moore SC, Weinstein SJ, Karoly ED, Sampson JN, Albanes D (2015) Metabolomic analysis of prostate cancer risk in a prospective cohort: the alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer 137(9):2124–2132. doi:10.1002/ijc.29576

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Mondul AM, Moore SC, Weinstein SJ, Mannisto S, Sampson JN, Albanes D (2014) 1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. Metabolomics 10(5):1036–1041. doi:10.1007/s11306-014-0643-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Dell’ Antone P (2012) Energy metabolism in cancer cells: how to explain the Warburg and Crabtree effects? Med Hypotheses 79(3):388–392

    Article  PubMed  Google Scholar 

  90. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140(1):49–61. doi:10.1016/j.cell.2009.11.027

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279(15):2610–2623. doi:10.1111/j.1742-4658.2012.08644.x

    Article  CAS  PubMed  Google Scholar 

  92. Lucarelli G, Rutigliano M, Galleggiante V, Giglio A, Palazzo S, Ferro M, Simone C, Bettocchi C, Battaglia M, Ditonno P (2015) Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Rev Mol Diagn 15(9):1211–1224. doi:10.1586/14737159.2015.1069711

    Article  CAS  PubMed  Google Scholar 

  93. Brandstedt J, Almquist M, Manjer J, Malm J (2012) Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control 23(8):1377–1385. doi:10.1007/s10552-012-9948-3

    Article  PubMed  Google Scholar 

  94. Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, Hoffman AR, Barrett-Connor E, Orwoll E, Beer TM (2010) Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 21(8):1297–1303. doi:10.1007/s10552-010-9557-y

    Article  PubMed  PubMed Central  Google Scholar 

  95. Wong YY, Hyde Z, McCaul KA, Yeap BB, Golledge J, Hankey GJ, Flicker L (2014) In older men, lower plasma 25-hydroxyvitamin D is associated with reduced incidence of prostate, but not colorectal or lung cancer. PLoS One 9(6):e99954. doi:10.1371/journal.pone.0099954

    Article  PubMed  PubMed Central  Google Scholar 

  96. Ordonez-Mena JM, Schottker B, Haug U, Muller H, Kohrle J, Schomburg L, Holleczek B, Brenner H (2013) Serum 25-hydroxyvitamin D and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prev 22(5):905–916. doi:10.1158/1055-9965.EPI-12-1332

    Article  CAS  PubMed  Google Scholar 

  97. Meyer HE, Robsahm TE, Bjorge T, Brustad M, Blomhoff R (2013) Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr 97(1):147–154. doi:10.3945/ajcn.112.039222

    Article  CAS  PubMed  Google Scholar 

  98. Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, Dupre N, Platz EA, Stampfer MJ, Giovannucci E (2012) Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst 104(9):690–699. doi:10.1093/jnci/djs189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM (2012) Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer 131(5):1187–1196. doi:10.1002/ijc.27327

    Article  CAS  PubMed  Google Scholar 

  100. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4(3):e103. doi:10.1371/journal.pmed.0040103

    Article  PubMed  PubMed Central  Google Scholar 

  101. Ordonez-Mena JM, Schottker B, Fedirko V, Jenab M, Olsen A, Halkjaer J, Kampman E, de Groot L, Jansen E, Bueno-de-Mesquita HB, Peeters PH, Siganos G, Wilsgaard T, Perna L, Holleczek B, Pettersson-Kymmer U, Orfanos P, Trichopoulou A, Boffetta P, Brenner H (2016) Pre-diagnostic vitamin D concentrations and cancer risks in older individuals: an analysis of cohorts participating in the CHANCES consortium. Eur J Epidemiol 31(3):311–323. doi:10.1007/s10654-015-0040-7

    Article  CAS  PubMed  Google Scholar 

  102. Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jorgensen T, Roswall N, Larsen SC, Linneberg A (2014) Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 23(7):1220–1229. doi:10.1158/1055-9965.EPI-14-0007

    Article  CAS  PubMed  Google Scholar 

  103. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A, Holick MF (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9(4):425–432

    Article  CAS  PubMed  Google Scholar 

  104. Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR (2004) Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89–90(1–5):533–537. doi:10.1016/j.jsbmb.2004.03.063

    Article  PubMed  Google Scholar 

Download references

Author’s contributions

AM Mondul, Project development, manuscript writing/editing; SJ Weinstein, Project development, manuscript writing/editing; D Albanes, Project development, manuscript writing/editing.

Author information

Authors and Affiliations

  1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA

    Alison M. Mondul

  2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive 6e342, Bethesda, MD, USA

    Stephanie J. Weinstein & Demetrius Albanes

Authors
  1. Alison M. Mondul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie J. Weinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Demetrius Albanes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Demetrius Albanes.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mondul, A.M., Weinstein, S.J. & Albanes, D. Vitamins, metabolomics, and prostate cancer. World J Urol 35, 883–893 (2017). https://doi.org/10.1007/s00345-016-1878-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-016-1878-3

Keywords

Search

Navigation